Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This phase II trial investigates how well lisinopril may work in preventing the progression
of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an
accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver
cancer. Liver fibrosis is the common finding of chronic liver diseases leading to reduced
liver function. Lisinopril is a medication that is commonly used to treat high blood
pressure. Lisinopril may help to decrease liver fibrosis. The purpose of this trial is to
find out what effect, if any, lisinopril has on a patient's risk of developing liver cancer.